Heidi E. Wang

Cooley represented Wugen, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies, on its oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Partner Tom Coll led the Cooley team.

Cooley represented Bright Peak Therapeutics, a biotechnology company developing next-generation immunotherapies to treat cancer and autoimmune disease, in its $107 million Series B financing led by RA Capital. Partner Tom Coll led the Cooley team.

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Cooley advised Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases, on its definitive agreement to sell to Pfizer for $6.7 billion. Partners Jamie Leigh, Kevin Cooper and Steve Przesmicki led the Cooley team advising Arena.